TUTimothy M. Uyeki

Timothy M. Uyeki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Timothy M. Uyeki has a total of 685 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Influenza Antiviral Treatment among Influenza Outpatients, PCORnet, 2022–2025 Influenza Seasons

    by Palak Patel, Emily Serman, Jason P Block, Tegan K Boehmer, Thomas W Carton, Kenneth H Mayer, Joshua L Denson, Jonathan Arnold, Faraz S Ahmad, Diane Emerton, et al.

    Analysis of PCORnet electronic health record data from 1.26 million outpatient influenza patients (2022–2025) found antiviral treatment prescribing was 41% overall and 44% among those at higher risk for complications. Lower prescribing may reflect multiple factors, including delayed care-seeking, suggesting opportunities to support more timely treatment and potentially reduce influenza-related complications.

  • How can veterinary personnel recognize and protect themselves from domestic cats infected with highly pathogenic avian influenza A(H5N1) viruses?

    by Lizette O. Durand, Sonja J. Olsen, Natalie M. Wendling, Timothy M. Uyeki, Grazia Mirabito, Tom T. Shimabukuro, Colin A. Basler

    Highly pathogenic avian influenza A(H5N1) viruses circulate globally in wild birds, causing poultry outbreaks and spillover infections in mammals and sporadic human infections. Recent detections in domestic cats highlight occupational risks for veterinarians handling cats in areas where A(H5N1) virus is circulating. Although the potential risk for cat-to-human A(H5N1) virus-transmission is currently low, vigilance is warranted. Veterinarians can use published recommendations to evaluate exposure risks, implement infection control practices, use recommended personal protective equipment, train staff, and coordinate with health officials. The One Health approach can help reduce risks of A(H5N1) virus infection to veterinary staff, cat owners, and other animals.

  • Open Access

    Investigation of a Family Cluster of Human Infections With Highly Pathogenic Avian Influenza A(H5N1) Virus, Clade 2.3.2.1e, in Cambodia, February 2023

    by Savuth Chin, Chansovannara Soputhy, Heng Seng, Sokly Mom, Borann Sar, Alyssa Finlay, Kathrine R. Tan, Philip L. Gould, Jurre Y. Siegers, Erik A. Karlsson, et al.

    In February 2023, an 11‐year‐old girl in Cambodia developed severe respiratory symptoms and died of pneumonia and respiratory failure after testing positive for influenza A(H5). Contract tracing and testing identified her father as positive for influenza A(H5). Investigations revealed both were likely exposed to the same sick and dead poultry. Control measures included culling sick poultry and providing health education in the community on handling infected birds. Highly pathogenic avian influenza A(H5N1) viruses continue to pose public health risks in Cambodia.


  • Open Access

    Oseltamivir and baloxavir monotherapy and combination therapy efficacy against clade 2.3.4.4b A(H5N1) influenza virus infection in ferrets

    by Jessica A. Belser, Nicole Brock, Xiangjie Sun, Troy J. Kieran, Joanna A. Pulit-Penaloza, Claudia Pappas, Hui Zeng, Larisa V. Gubareva, Timothy M. Uyeki, Taronna R. Maines

    Neuraminidase inhibitors (NAIs) and cap-dependent endonuclease inhibitors (CENIs) represent two classes of antiviral drugs recommended for early treatment of patients with seasonal influenza A virus (IAV) infections. However, only limited human data, particularly on combination antiviral treatment, are available to inform optimal dosing regimens against novel IAVs, including highly pathogenic avian influenza A(H5N1) virus, associated with severe disease. Clade 2.3.4.4b A(H5N1) viruses have caused outbreaks in avian and mammalian species worldwide, highlighting the need to assess antiviral drug efficacy against these strains. We challenged ferrets with a D1.1 genotype A(H5N1) virus and treated infected animals with the NAI oseltamivir phosphate (OST) and the CENI baloxavir acid (BXA), alone or in combination, with treatment onset commencing pre- or post-symptom onset (24- or 48-hours post-inoculation (p.i.), respectively). When administered pre- or post-illness onset, BXA, but not OST, monotherapy provided significant reduction of clinical signs and significantly decreased infectious viral levels (in both respiratory and extrapulmonary specimens) compared with mock-treated animals. Combination OST/BXA treatment, when administered pre- or post-symptom onset, resulted in significant improvements in both metrics versus OST monotherapy. These data support continued investigation of antiviral treatment modalities that include both NAI and CENI for patients with mild and severe A(H5N1) disease.


  • Open Access

    A Cross‐Sectional Virological and Sero‐Epidemiological Study of Exposures to Avian Influenza A(H5N1) and A(H9N2) Viruses in Live Bird Market Workers in Dhaka, Bangladesh

    by Mahbubur Rahman, Timothy M. Uyeki, Malik Peiris, Jacqueline M. Cardwell, Patrick Nguipdop‐Djomo, Min Kim, A. S. M. Alamgir, A. K. M. Muraduzzaman, Sudipta Sarkar, Md Giasuddin, et al.

    Background: Avian influenza A viruses (AIVs) are endemic among poultry in Bangladesh sold at live bird markets (LBMs). We assessed virologic and serologic evidence of exposure to AIVs among LBM workers. Methods: A cross‐sectional study recruited 702 randomly sampled workers from 42 LBMs in Dhaka, Bangladesh, during 2017. Nasal and throat swabs collected from workers and air samples from LBMs were tested for influenza A virus by RT‐PCR with positives subtyped for A(H5), A(H7), and A(H9). Baseline sera from 695 workers and follow‐up sera from 89 workers with influenza A positive respiratory specimens were tested by microneutralization assay for antibodies to A(H5N1) clade 2.3.2.1a and A(H9N2) G1 lineage viruses circulating in poultry. A seropositive result was defined as a neutralizing antibody titer ≥ 1:40. Results: Most LBM workers reported slaughtering (93.3%) and defeathering (84.5%) poultry. Ninety‐nine (14.1%) had ≥ 1 respiratory specimen that tested influenza A positive but negative for A(H1) and A(H3). Of these 99, subtyping identified 28 (28.3%) A(H9), 2 (2%) A(H5), 3 (3%) both A(H5) and A(H9), and 66 (66.7%) A (nonsubtypeable). Influenza A viruses were detected in air samples at 25 LBMs (59.5%), including A(H9) only in 10 LBMs (40%), A(H5) only in one (4%), both A(H5) and A(H9) in 13 (52%), and one A (nonsubtypeable) (4%). None of the participants were seropositive for AIVs. Conclusions: LBM workers had extensive exposure to AIVs, but none had serologic evidence of infection with A(H5N1) or A(H9N2) viruses circulating among poultry in Bangladesh. Ongoing surveillance of AIVs in LBMs and poultry workers is needed.


  • The Role of Antiviral Treatment of Influenza in Reducing Hospitalizations and Other Severe Outcomes: A Need for More Evidence

    by Mark W Tenforde, Shikha Garg, Jessie Chung, Katherine Adams, Timothy M Uyeki

    More evidence is needed to define the benefits and role of antiviral treatment to reduce risk of severe influenza outcomes based on clinical risk factors and timing. Well-conducted real-world observational studies can complement evidence from randomized controlled trials to address critical gaps.

  • Open Access

    Human infections with avian influenza a(H5) viruses with potential pandemic risk: 1997-2025

    by Wei Wang, Jiabao Xing, Hui Jiang, Fayu Lu, Haoxuan Huang, Yuqian Zhang, Andi Sun, Yi Han, Jian Lu, Benjamin J Cowling, et al.

    Highly pathogenic avian influenza (HPAI) A(H5) viruses have caused sporadic human infections since 1997, with recent detections in the Americas and Asia. However, the evolutionary dynamics of different HPAI A(H5) viruses at the animal-human interface, along with their associated disease severity, propensity for animal-to-human (zoonotic) spillover, and human-to-human transmission potential, remain unclear. Here, we combine available genetic and epidemiological data with mechanistic models to better understand global spread of HPAI A(H5) viruses that spilled over to humans in 1997–2025. Analysis of 7445 subsampled hemagglutinin gene sequences revealed frequent regional succession of HPAI A(H5) virus clades that varied by geographic location. The 1104 reported human HPAI A(H5) cases exhibited subtype- and clade-specific heterogeneity in age, gender, and exposure sources (p < 0.001). After adjusting for under-reporting, we estimated case-fatality risk to be low for HPAI A(H5N1) clade 2.3.4.4b (0.7%, 95%CI 0.02–3.9%) and for A(H5N6) clades 2.3.4x (0%, 0–1.1%) and 2.3.4.4b (1.6%, 0.7–3.2%), compared with other A(H5) clades (range: 4.7–15.0%). We also show that, while the transmissibility of HPAI A(H5) viruses between humans remains very low to date (mean Rt: 0.10–0.23), zoonotic transmission has increased with the emergence of bovine-origin clade 2.3.4.4b (incidence: 7.85 per million people per year), relative to other avian-origin A(H5) clades (range: 1.54–5.04 per million people per year). Although other factors such as exposure sources, routes of transmission, immune function, underling medical conditions, and clinical management can influence outcomes of case-patients, these findings highlight the ongoing pandemic threat posed by HPAI A(H5) viruses and the need for ongoing comprehensive surveillance, genotypic and phenotypic characterization, and preparedness.


  • Antivirals for Novel Influenza A Virus Infections

    by Timothy M Uyeki, Jessica A Belser

    Influenza A viruses of animal origin (such as avian or swine influenza A viruses), which are antigenically and genetically distinct from seasonal influenza A viruses and have infected humans, are referred to as novel influenza A viruses. Sporadic human infections with highly pathogenic avian influenza A(H5N1) viruses of a wide spectrum of illness severity in the United States and worldwide have highlighted the need for evidence-based recommendations on the use of antivirals for novel influenza A virus infections. We review the available published data on use of antivirals for humans with novel influenza A virus infections of avian [A(H5N1), A(H5N6), A(H7N7), and A(H7N9) viruses associated with severe human disease] or swine origin, and data from in vivo antiviral studies. We summarize the available evidence on the effectiveness of antiviral treatment and antiviral postexposure prophylaxis of novel influenza A virus infections, discuss considerations for use of combination therapy with antivirals of different mechanisms of action, and identify important questions to improve the evidence base and to further guide use of antivirals for treatment and postexposure prophylaxis of novel influenza A virus infections.


  • Top Cited Papers

    Human infections with highly pathogenic avian influenza A(H5N1) viruses in the United States from March 2024 to May 2025

    by Melissa A. Rolfes, Krista Kniss, Marie K. Kirby, Shikha Garg, Katie Reinhart, C. Todd Davis, Erin L. Murray, Debra A. Wadford, Kathleen Harriman, Sophie Zhu, et al.

    Between March 2024 and October 2024, 46 human cases of highly pathogenic avian influenza (HPAI) A(H5N1) had been detected in the United States. The persistent panzootic spread of HPAI A(H5N1) viruses and continued detection of human cases presents an ongoing threat to public health. Between November 2024 and May 2025, an additional 24 cases have been reported for a total of 70 human cases of HPAI A(H5N1): 41 were exposed to dairy cows, 24 to commercial poultry, 2 to backyard poultry, and 3 had an unidentified source of exposure. All sequenced viruses were clade 2.3.4.4b. Overall, 62 cases (89%) reported eye redness, 32 (46%) fever, and 29 (41%) respiratory symptoms; 54 of 67 cases (81%) reported receiving antiviral treatment. Most illnesses were mild; however, four patients were hospitalized. Of the hospitalized patients, three had pneumonia and one died. No human-to-human transmission was detected. Occupational exposure to infected animals was a risk factor for HPAI A(H5N1) virus infection and the risk to the general population remains low; however, the two cases exposed to infected backyard poultry and three cases with unidentified exposures highlight that ongoing vigilance is warranted.


  • Open Access

    Epidemiology of Human Metapneumovirus Infection in a Community Setting, Seattle, Washington, USA

    by Annalyse Elias-Warren, Julia C Bennett, Chidozie D Iwu, Lea M Starita, Jeremy Stone, Ben Capodanno, Robin Prentice, Peter D Han, Zack Acker, Sally B Grindstaff, et al.

    Background: The clinical and genomic epidemiology of human metapneumovirus (hMPV) infections in community settings is not well understood. Methods: From 2018 to 2022, individuals with respiratory symptoms were recruited and enrolled from the greater Seattle, Washington community in the United States. Residual clinical specimens from individuals presenting with respiratory symptoms were additionally collected. Specimens were tested for hMPV by reverse-transcription polymerase chain reaction, with whole genome sequencing performed on a subset (209/1002). Results: hMPV positivity was higher among clinical specimens (835/21 539 [3.9%]) compared to community specimens (167/28 348 [0.6%]). Children aged 0–4 years had the highest percent positivity across both clinical and community settings (497/10 213 [4.9%] and 28/1640 [1.7%], respectively). In multivariate analysis, a household income of ≤US$100 000 (adjusted odds ratio [aOR], 1.72 [95% confidence interval {CI}, 1.07–2.85]), and recent international travel (aOR, 6.51 [95% CI, 3.11–12.22]) were associated with hMPV positivity. A subset of 209 of 1002 samples (21%) was sequenced; the distribution of subtypes A2b, A2c, B1, and B2 were similar across both community and clinical settings, with an increase in the proportion of subtype B1 after the start of the pandemic. Conclusions: Risk factors of testing positive for hMPV in a community setting included lower household income and recent international travel. Co-circulation of hMPV subtypes was observed across community and clinical settings.